Table 2. Association of proliferation markers with clinicopathologic variables.
| Proliferation biomarker | Clinicopathologic parameter | P-valuea |
| Ki-67 | Preoperative PSA (≥10 vs. <10 ng/ml) | 0.85 |
| Gleason grade (≥4+3 vs. ≤3+4)b | 0.20 | |
| Pathologic stage (≥T3a vs. ≤T2b)c | 0.24 | |
| TOP2A | Preoperative PSA (≥10 vs. <10 ng/ml) | 1.0 |
| Gleason grade (≥4+3 vs. ≤3+4)b | 0.12 | |
| Pathologic stage (≥T3a vs. ≤T2b)c | 0.06 | |
| E2F1 | Preoperative PSA (≥10 vs. <10 ng/ml) | 0.73 |
| Gleason grade (≥4+3 vs. ≤3+4)b | 0.82 | |
| Pathologic stage (≥T3a vs. ≤T2b)c | 0.39 |
a
Two-sided Fisher's exact test.
b
Stratification based on limited representation of Gleason 6 and 4+4 cases.
c
Stratifies pathologic stage based on organ confinement.